Impact of Dolutegravir-based regimens on patient satisfaction and quality of life among people living with HIV: a systematic review and meta-analysis Authors: Mustapha Muhammed Abubakar, Christabel Ogechukwu Okoye, Ruth Jeminiwa, Ifeanyi Kanayo Ifeorah, Lotanna Ezeja, Yusuf Dauran, Sahabi Musa, Silas Usen Joel, Abdurrahman Murtala Bello, Amauche Pearl Ngige, Gabriel Ezenri, Abdulmuminu Isah, Ifunanya Ikhile, Blessing Onyinye Ukoha-Kalu Published: 2026 ABSTRACT AbstractBackgroundDespite the global scale up of dolutegravir (DTG)-based regimens as the preferred first-line therapy for persons living with HIV (PLHIV), no comprehensive evidence exists on its effect on patient-reported outcomes such as Quality of Life (QoL) and patient satisfaction (PS). We conducted a systematic review and meta-analysis to provide the first comprehensive quantitative synthesis of the effect of DTG-based regimens on QoL and PS among PLHIV.MethodWe conducted literature search on PubMed, Scopus, Embase and Cochrane Library databases for peer-reviewed, primary studies published from January 2015 to January 2025. Studies using validated tools to evaluate QoL and PS among PLHIV exposed to DTG were eligible. Standardised Mean Differences (SMD) were computed using DerSimonian-Laird random-effects model. Certainty of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework. The study protocol was registered on PROSPERO (CRD42025643301).ResultsSeventeen out of the 214 (n = 4064) identified studies met the inclusion criteria, with six contributing to the QoL meta-analysis and four to the PS meta-analysis. The pooled QoL estimate showed a small improvement favoring DTG-based regimens compared to other antiretroviral therapy (ART) though not statistically significant (SMD: 0.094, 95% CI: -0.034–0.223; p = 0.15; GRADE: Very Low). With the WHOQOL-HIV BREF tool subgroup, a positive directional effect was also observed (SMD: 0.09, 95% CI: -0.042–0.22, p = 0.18; I2 = 0.0%) compared to other ART, though not statistically significant. DTG-based regimens were associated with a statistically significant improvement in PS (SMD = 0.3; 95% CI: 0.2–0.4; p < 0.001; I2 = 10.7; GRADE: Low). Among studies that used the HIV Treatment Satisfaction Questionnaire to evaluate PS, the effect of DTG-based regimens was also statistically significant (SMD: 0.32, 95% CI: 0.2–0.45, p < 0.001; I2 = 34%).ConclusionThis review identified a directional improvement in QoL and a statistically significant small improvement in PS among PLHIV on DTG-based regimens. Findings from this study were supported by low between-study heterogeneity. However, findings should be interpreted in the context of low and very low certainty of evidence for both outcomes. Additionally, results from this study are best characterized as hypothesis-generating and supportive of person-centered HIV care, underscoring the need for more well-designed trials to generate high-certainty evidence on patient-reported outcomes among PLHIV.Clinical trial numberNot applicable.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12879-026-13559-1.Keywords: HIV, Dolutegravir-based regimens, Patient satisfaction, Quality of life, Systematic review, Meta-analysis Introduction The introduction of antiretroviral therapy (ART) has transformed HIV infection from a fatal disease into a manageable chronic condition, significantly extending life expectancy to nearly match that of the general population and improving clinical outcomes among people living with HIV (PLHIV) [1–3]. Currently, HIV treatment guidelines recommend that dolutegravir (DTG) with a nucleoside reverse transcriptase inhibitor (NRTI) backbone be used as first-line treatment, and second-line treatment for PLHIV that experienced treatment failure with non-nucleoside reverse transcriptase inhibitors (NNRTIs) in their regimen [4, 5]. This is supported by evidence that DTG has minimal adverse effects, fewer drug interactions, once daily dosing, and favorable safety profile [6–8]. Thus, as at 2021, over 22 million PLHIV had switched to DTG-based regimens [5]. Beyond the pharmacological efficacy and viral suppression rates that have long dominated HIV research, a more patient-centered approach is emerging that prioritizes patient reported outcomes such as patient satisfaction (PS), quality of life (QoL), and the overall experience of PLHIV [9, 10]. As PLHIV live longer and healthier lives, the clinical focus has now expanded from viral control to encompass psychosocial well-being, treatment convenience, tolerability, and satisfaction with care, which are all key determinants of medication adherence and better patient-reported outcomes. Patient-reported outcomes are defined as “any report of the status of a patient’s health condition that comes directly from the patient without interpretation of the patient’s response by a clinician or anyone else”. They encompass a broad range of constructs including symptoms, functional status, general perceptions of well-being, satisfaction with treatment and QoL [11]. QoL is defined as “an individual’s perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns” [12]. The concept of QoL is multi-dimensional, integrating subjective and objective aspects of wellbeing across physical, mental, and social health domains [13, 14]. ART-exposed individuals who adhere well to their medication, receive strong social support, and have better access to healthcare report higher QoL [15–17]. On the other hand, PS can be defined as an individual’s cognitive and emotional assessment of their healthcare experience [18]. Studies have shown that PLHIV with higher levels of satisfaction tend to demonstrate improved medication adherence and treatment outcomes [13, 19]. With improved comparative efficacy and safety, DTG-based regimens have the potential to enhance patient-reported outcomes. Some reports suggest that DTG’s simplified dosing and minimal side effect profile contribute to improved PS and QoL [20–22]. Conversely, there are concerns about neuropsychiatric effects, weight gain, or gender-specific tolerability that could dampen its overall satisfaction and benefits [23–27]. Currently, there is paucity of global evidence assessing these patient-reported outcomes among PLHIV on DTG-based regimens. Further, evidence in literature is limited and fragmented, with variance in study designs, measurement tools, populations and outcome measures. Consequently, a comprehensive review and analysis is needed to evaluate the impact of DTG-based regimens on PS and QoL among PLHIV. Despite the widespread adoption of DTG-based regimens as the WHO-preferred first-line ART globally, evidence on their impact on QoL and PS remains fragmented across heterogeneous study designs, measurement tools and study populations, limiting definitive conclusions from individual studies. This limitation underscores the need for formal quantitative synthesis. No prior systematic review or meta-analysis has comprehensively addressed this gap, leaving clinicians and policymakers without a basis for considering the patient-centered benefits of DTG-based regimens beyond viral suppression. As outlined in our protocol [28], this systematic review and meta-analysis aim to fill this gap by providing the first quantitative synthesis of the effects of DTG on PS and QoL among PLHIV. Additionally, subgroup analyses will also be conducted to assess the source of heterogeneity of pooled estimates, uncover disparities and inform more personalized treatment strategies. Through this work, we seek to support evidence-based clinical decision-making and policy formulation, advancing the broader goal of person-centered care in HIV treatment and management. Methods Search strategy Literature search was conducted on PubMed, Scopus, Embase and Cochrane Library databases to cover for the period of 1 January 2015 to 1 January 2025. Keywords for the search were: Dolutegravir, quality of life and patient satisfaction. MMA, COO and BUK independently developed and implemented all search strategies. For the purpose of identifying sensitive and widely used terminologies, we searched for peer-reviewed, published systematic reviews and operationalised the key words of quality of life and patient satisfaction [29–31]. These systematic reviews informed keyword selection only and were not eligible for inclusion as primary data sources. The complete search strategy is detailed at Appendix 1. MMA, COO and AMB screened the articles on Microsoft Excel by removing all duplicates as well as reading the title and abstracts of the papers. For the articles that met our inclusion criteria, we read the full text to determine whether to finally include it. Where both reviewers could not reach a consensus, another reviewer, RJ broke the tie. Inter-rater agreement for study selection decisions was assessed using Cohen’s kappa statistic. This systematic review and meta-analysis protocol is registered on PROSPERO with the identification number, CRD42025643301. Eligibility criteria We included peer-reviewed original studies that used validated assessment tools to evaluate QoL and PS among PLHIV exposed to DTG. For studies where the study population was exposed to other integrase strand transfer inhibitors (INSTIs) or other ART classes, we collected data separately for the outcomes of those exposed to DTG and those of the comparator. Where comparisons were done between DTG-exposed and DTG-naïve populations, we reported both. In instances, where there was no comparator intervention, we reported only the endpoint values for the DTG group. Additionally, the search was restricted to January 2015 to January 2025, anchored on the WHO’s 2015 guideline release recommending ART initiation for PLHIV regardless of CD4 cell count and the subsequent period of progressive DTG adoption into national and international treatment guidelines. The upper limit of this period was set to capture the most recent evidence. Conversely, we excluded the following types of publications: case studies, commentaries, editorials, and all forms of reviews. Grey literature including conference abstracts, dissertations, preprints and unpublished reports was not systematically included in this review as they could potentially be sources of publication bias. Further, we excluded articles that did not utilize validated measurement tools to evaluate QoL and PS. This review employed the Preferred Reporting Items for Systematic Review and Meta-analysis 2020 Statement (an updated guideline for reporting systematic reviews) [32]. Data extraction and quality assessment The following data were extracted from each of the included study: first author and publication year, country, sex, study design, sample size and mean age of participants. Further, period of DTG exposure, assessment tools for outcomes, mean QoL and PS would be extracted. Also, proportions of PLHIV satisfied with treatment were also extracted. Quality assessment was guided by the study design of included studies, as no single appraisal tool is validated across all designs. For cross-sectional studies, the Newcastle-Ottawa Scale would be used to assess for quality of the included studies. The Scale assigns a maximum of 9 points based on the selection, comparability, and outcome parameters. The Joanna Briggs Institute (JBI) Checklist for Cohort Studies was used to assess for the cohort studies that met our eligibility criteria. The Critical Appraisal Skills Program (CASP) for Randomized Clinical Trials (RCTs) was employed to assess for the quality of evidence of included RCTs. Additionally, the Risk of Bias in Non-randomized Studies – of Interventions, Version 2 (ROBINS-I V2) was used for quality assessment of the non-randomised interventional studies. Quality assessment was performed by three independent authors (MMA, COO, and AI). Doubts and ties were resolved by contacting a third reviewer, BUK. The certainty of evidence for each pooled outcome was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework [33]. Assessment for certainty of evidence was done across the five domains of risk of bias, inconsistency, indirectness, imprecision and publication bias. Randomised controlled trials were assigned a default starting certainty of High and observational studies of Low, with mixed designs rated at Moderate, where designs contributed approximately equal studies. Certainty was downgraded for each domain judged as serious. Data analysis and synthesis Primary outcome was the mean values of the QoL and PS validated tools. Secondary outcome was the proportions of patients satisfied with DTG use. For quantitative synthesis, the primary outcome was change from baseline score within the DTG and comparator regimen arms. Standardised Mean Difference (SMD) computed as the Hedges’g using the DerSimonian-Laird random effects estimator was used as the effect measure. Hedges’g expresses each study’s between arm difference in change scores in units of the pooled within-study standard deviation, rendering it directly comparable across instruments regardless of original scale range. We computed SMD with their 95% Confidence Intervals (CI). Magnitude of SMDs were interpreted using the Cohen’s matrix: small, SMD = 0.2–0.5; medium, SMD = 0.5–0.8; and large, SMD > 0.8 [34]. To address the use of different measurement scales to assess outcomes, we standardized outcome scores to allow cross-instrument comparability and eventual pooing analysis. For studies that reported the standardized differences of change scores directly, we used these estimates. For studies reporting medians and interquartile ranges, the standard deviation was computed as SD = IQR/1.35 [35]. For studies reporting group means and a p-value without standard deviations, SDs were recovered by inverting the two-sample t-test using the reported group sample sizes and p-value [36]. For studies lacking a baseline measure or where outcomes are inconsistent enough for a meta-analysis, we included them for narrative synthesis only without pooling estimates. Additionally, we pooled the mean values of QoL and PS from studies per measurement tool if the tool was used in more than one study. We aimed to conduct a subgroup analysis (where studies = 10) to assess the possible influence of heterogeneity. Statistical heterogeneity was assessed using the I2 statistics. Funnel plot visualization and the Egger’s regression test was used to ascertain publication bias. All analysis was conducted on the statistical environment RStudio, version 4.2.1. We used the escalc function under the metafor library to compute effect sizes, while random effect sizes were fitted via rma function. For data wrangling, we used the dplyr package. Results Study selection process A total of 214 studies were identified from PubMed (n = 64), Scopus (n = 27), Embase (n = 29_ and Cochrane Library (n = 94). Subsequently, 16 duplicates were identified and removed. Following the application of our eligibility criteria, 181 studies were excluded. Consequently, 17 studies were included in the review. Inter-rater agreement was substantial (k = 0.81). Figure 1 shows the study selection process. Flow diagram of the study selection process using the updated guideline for reporting new systematic reviews [32] Study characteristics This review included 17 studies that reported on the effect of DTG-based regimens on QoL and PS [20, 22, 37–51]. Eight studies primarily assessed for the impact of DTG-based regimens on QoL [37–44] while another eight studies reported on PS upon exposure to dolutegravir-based ART [20, 22, 45–50]. Notably, Pane et al. reported on both QoL and PS among PLHIV who transitioned from an NVP-based regimen to a DTG-based regimen [51]. We also computed the total study population as 4064. Characteristics of QoL studies Four out of the 8 QoL studies were randomized controlled trials [37, 39, 41, 42] while three utilized the cross-sectional study design [38, 40, 43]. Two studies employed cohort study design [44, 51]. Per geographical location, two studies were conducted in Europe (Germany and Switzerland) [37, 42] while three studies were set in South America [38, 43, 44]. Further, two studies were conducted in Africa [39, 40]. Pane et al. was set in Asia [51]. Sample size ranged from 103 to 399 [40, 43]. Regarding sex distribution, one study focused on only pregnant women [39]. However, six out of the nine studies that assessed for QoL among PLHIV had > 80% male study participants (Table 1). Table 1Characteristics of all included papers in the systematic review and meta-analysisFirst AuthorStudy designLocationStudy sampleAge description(years)% maleMehari et al. 2021Cross-sectionalEthiopia349Mean = 40.2845Olliges et al. 2022RCTGermany263Median age: 4890.1Hong et al. 2022Cross-sectionalUkraine210Mean = 40 +- 9.345.3Costa et al. 2019Cross-sectional, observationalBrazil366Mean = 34.183.3Poliseno et al. 2023CohortItaly95Mean = 5861Ochanda et al. 2022RCTUganda/SA171Mean = 280Pane et al. 2025CohortIndonesia145Median: 4357.2Gudala et al. 2025Cross-sectionalSouth Africa103Mean = 41.751.5Kumar et al. 2025RCTmulti-center493Median age: 4561Allavena et al. 2019Non-randomized, single-arm, non-comparative study NM 106Median age: 52.571.7Sculier et al. 2020RCTmulti-center187Median age: 4883Mendes et al. 2018Cross-sectionalBrazil399Mean = 3482.7Hidalgo-Tenorio et al. 2022Non-randomizedSpain88Mean = 35.987.5Trottier et al. 2017RCTUnited States & Canada553Mean = 4586Pimentel et al. 2020CohortBrazil308Mean = 34.583Rossetti et al. 2025RCTItaly41Mean = 5378Marinosci et al. 2024RCTSwitzerland187Mean = 4883Key - NM: not mentioned; SA: South Africa; RCT: randomized controlled trials; QoL: Quality of Life; PS: patient satisfaction Characteristics of all included papers in the systematic review and meta-analysis Key - NM: not mentioned; SA: South Africa; RCT: randomized controlled trials; QoL: Quality of Life; PS: patient satisfaction Characteristics of PS studies Three of the 8 studies were randomized controlled trials [46, 49, 50] while two were cross sectional studies (Mehari et al.; Hong et al.). Two studies were non-randomized interventional studies [47, 48]. One study employed the cohort study design [45]. Notably, four of the eight studies were conducted in Europe [20, 45, 48, 50] while a study each was set in North America [49] and Africa [22]. Sample size of participants in the included studies ranged from 41 to 553 [22, 48]. Male population included in the studies ranged from 45% to 87.5% [22, 48] (Table 1). Scales of measurement All included studies in this review assessed outcomes using a measurement tool. Notably, all measurement tools reported were validated. Measurement tools used in QoL studies Four tools were used in the QoL studies. These are WHOQOL HIV BREF, PROQOL-HIV, MOS-HIV, and EQ-5D tools. Four studies used the WHOQOL HIV BREF tool in the evaluation of QoL among PLHIV [38, 40, 43, 44]. PROQOL-HIV [41, 42] and EQ-5D [38, 51] were used to assess QoL in two studies each. Also, two studies employed the MOS-HIV tool [37, 39]. Costa et al. employed both the WHOQOL-HIV BREF and EQ-5D to assess the study outcome. Description of QoL tools used The WHOQOL-HIV BREF tool, a tool specifically to assess QoL among PLHIV, comprises 31 questions covering the six domains of physical, psychological, level of independence, social, environmental and spiritual. The mean of each domain is used to provide estimate for the total QoL score. Overall score of QoL, according to the tool, range from 4 to 20, with higher scores indicating improved QoL [52]. The PROQOL-HIV is a 43-item questionnaire covering eight domains and general health. The eight domains are physical health and symptoms, treatment impact, emotional distress, health concerns and body change. Other domains are intimate relationships, social relationships and stigma. The tool utilizes a 5-point Likert scale with responses ranging from 0 to 4. Scores from the responses are standardized on a scale of 0-100, with higher values implying better QoL [53, 54]. MOS-HIV, another tool used specifically in the evaluation of QoL among PLHIV, is a brief instrument consisting of 30 items across 11 dimensions. Higher scores indicate higher QoL, with the scale ranged from 0 to 100 [55]. The EuroQoL-5D or EQ-5D has a section for the indirect measure of QoL using five questions. The five domains assess mobility, self-care, usual activities, pain and anxiety/depression. Scores from these domains are used to define the health status parameter which ranges from 0 to 1. The low score of 0 refers to death and the maximum score of 1 represents full health [56]. Measurement tools in PS studies Three measurement tools were used in the eight studies that assessed for PS. The tools reported were TSQM, HIVTSQ and EQ-VAS. Five out of the eight studies utilized the HIVTSQ tool in the assessment of QoL [20, 45–47, 49] while two studies used TSQM [22, 50]. Hidalgo-Tenorio et al. used the EQ-VAS to measure the study outcome [48]. Description of measurement tools used in PS studies The HIV Treatment Satisfaction Questionnaire or HIVTSQ is a validated patient-reported outcome assessment tool to evaluate the perception of treatment satisfaction among PLHIV on ART regimen. HIVTSQ items are typically rated on a six-point Likert scale covering general treatment satisfaction and clinical subscales. Overall satisfaction scores are calculated from the domain scores resulting in a total score of 0–66 or computed to a scale of 0-6.6 [57, 58]. The Treatment Satisfaction Questionnaire with Medication (TSQM) is a measure of patient satisfaction with medication. PS assessment is based on responses to questions focused on effectiveness, side effects, convenience and global satisfaction [59]. Typically, overall scores are scaled 0-100, with higher scores implying higher satisfaction with medication. The second part of the EuroQoL-5D is the Visual Analog Scale or EQ-VAS utilized in assessing the overall patient health status. Perceived health status is scored 0-100, with higher scores representing best imaginable health state. DTG-based regimens Across the studies included in this review, we identified six distinct DTG-based regimens among PLHIV. Six out of the 17 studies reported the interventional regimen to be DTG/TDF/3TC [22, 38, 40, 43, 44, 51] and three papers assessed on the impact of DTG/ABC/3TC on the outcomes of this review [47, 49, 50]. Two studies reported on DTG/3TC [46, 48] and DTG/FTC [41, 42]. Olliges et al. and Poliseno et al. assessed the effects of DRV/r/DTG and DTG/DOR on QoL and PS respectively (Table 2). Table 2Summary of outcome data and synthesis classification for all included studiesFirst Author, Year (Study)Measurement ToolOutcome FormatTime PointDTG Arm: Score ± SD or Median [IQR]Comparator Arm: Score ± SD or Median [IQR]n, DTGn, ComparatorSynthesis TypeCountry Quality of Life Ochanda et al., 2022MOS-HIVEndpoint meanWeek 48DTG: 15.71 ± 22.00EFV-based: 12.66 ± 19.058289Meta-analysisUganda / South AfricaSculier et al., 2020PROQOL-HIVChange from baselineWeek 48DTG/FTC: Mean change: +2.9cART: +0.3; Adjusted difference: +2.69394Meta-analysisSwitzerlandCosta et al., 2019aWHOQOL-HIV BREFEndpoint medianCross-sectional, 65 daysDTG/3TC/TDF: 16.0 (14.0–18.0)EFV/3TC/TDF: 16.0 [14.0–18.0] p = 0.358104262Meta-analysisBrazilMendes et al., 2018bWHOQOL-HIV BREFEndpoint mean (domains averaged)Cross-sectional, 92 daysDTG/3TC/TDF: 15.47 ± 2.58 (avg. 6 domains)EFV/3TC/TDF: 14.87 ± 3.04 (avg. 6 domains)106293Meta-analysisBrazilPimentel et al., 2020cWHOQOL-HIV BREFChange from baseline77 daysDTG/3TC/TDF: Mean change: 1.02 ± 2.83EFV: Mean change = 0.83 ± 3.44104204Meta-analysisBrazilOlliges et al., 2022MOS-HIVEndpoint mean (OR-based model)Week 482DR (DTG + DRV/r) baseline: 69.743DR (2NRTIs + DRV/r) baseline: 73.67131132Meta-analysisGermanyGudala et al., 2025WHOQOL-HIV BREFEndpoint meanCross-sectional, > 4 weeksDTG/3TC/TDF: 14.32 ± 1.91single arm103nilNarrativeSouth AfricaMarinosci et al., 2024PROQOL-HIVOnly threshold reportedWeek 144> 80/100> 80/100 (cART)9394NarrativeSwitzerland Patient Satisfaction Trottier et al., 2017HIVTSQChange from baselineWeek 48DTG/3TC/ABC: Adj.diff + 2.4 (95%CI 1.3–3.5; p < 0.001)cART275278Meta-analysisUSA / CanadaKumar et al., 2025HIVTSQBetween-group change (week 48)Week 48DTG/3TC: W4: +1.8 [0.9–2.6] W24: +1.4 [0.7–2.2] W48: +1.4 [0.7–2.2]cART246247Meta-analysismulti-countryHong et al., 2022HIVTSQEndpoint meanCross-sectional, 58 monthsDTG: 5.12EFV: 4.92 LPV: 4.5988LPV-based = 47; EFV-based = 75Meta-analysisUkraineAllavena et al., 2019HIVTSQMedian (Pre-post switch)Week 48DTG/3TC/ABC: Post-switch: 58Pre-switch: 54 (diff = + 4)53nilMeta-analysisFranceRossetti et al., 2025*TSQMEndpoint meanWeek 48DTG/ABC/3TC: 5.47 ± 1.89BIC/FTC/TAF: 6.50 ± 0.782021NarrativeItalyMehari et al., 2021TSQMEndpoint medianCross-sectional, (8.3 year)DTG/TDF/3TC: 83.3 (75–100)single arm349nilNarrative onlyEthiopiaPoliseno et al., 2023*HIVTSQEndpoint medianWeek 37DOR + DTG: 58 (50–65)DOR + RAL: 68 [64–72] p < 0.0014352Narrative onlyItalyHidalgo-Tenorio et al., 2022EQ-VASEndpoint medianWks 4, 24, 48DTG/3TC: W4: 90 (80–95)W24: 90 [80–100] W48: 90 (85–100)single arm88nilNarrative onlySpain Quality and Patient Satisfaction Pane et al., 2025EQ-5D-VASEndpoint medianPost-switchDTG/TDF/3TC: Post: 90 (85–100)Pre: 90 [80–99] p < 0.001145nilNarrativeIndonesiaAbbreviations: DTG = dolutegravir; EFV = efavirenz; LPV = lopinavir/ritonavir; cART = combination ART; 2DR = two-drug regimen; 3DR = three-drug regimen; DOR = doravirine; RAL = raltegravir; BIC = bictegravir; ABC = abacavir; 3TC = lamivudine; CAR = continued antiretroviral regimen; IQR = interquartile range; SD = standard deviation; HIVTSQ = HIV Treatment Satisfaction Questionnaire; TSQM = Treatment Satisfaction Questionnaire for Medication; PROQOL-HIV = Patient-Reported Outcomes Quality of Life–HIV; MOS-HIV = Medical Outcomes Study–HIV; WHOQOL-BREF = World Health Organization Quality of Life–HIV BREF; EQ-5D = EuroQol 5-Dimension* Both arms contain an INSTI. Retained as narrative only Summary of outcome data and synthesis classification for all included studies Abbreviations: DTG = dolutegravir; EFV = efavirenz; LPV = lopinavir/ritonavir; cART = combination ART; 2DR = two-drug regimen; 3DR = three-drug regimen; DOR = doravirine; RAL = raltegravir; BIC = bictegravir; ABC = abacavir; 3TC = lamivudine; CAR = continued antiretroviral regimen; IQR = interquartile range; SD = standard deviation; HIVTSQ = HIV Treatment Satisfaction Questionnaire; TSQM = Treatment Satisfaction Questionnaire for Medication; PROQOL-HIV = Patient-Reported Outcomes Quality of Life–HIV; MOS-HIV = Medical Outcomes Study–HIV; WHOQOL-BREF = World Health Organization Quality of Life–HIV BREF; EQ-5D = EuroQol 5-Dimension * Both arms contain an INSTI. Retained as narrative only Comparator or control regimens In 14 studies, there were reported comparisons between DTG-based regimens and other ART regimens with regards improvement in QoL and PS [20, 37–39, 41–47, 49–51]. A diverse range of ART was identified as comparator regimens in this review. Five studies compared EFV-based regimens to DTG-based regimens [20, 38, 39, 43, 44]. Similarly, four studies broadly reported combined ART (cART) as the comparator regimen [41, 42, 46, 49]. Two studies compared other INSTI regimens to DTG using BTC/FTC/TAF and DOR/RAL [45, 50]. One study compared ABC/3TC/NVP to DTG-based regimens [47]. Impact of DTG-based regimens on QoL Three studies reported on the effect of DTG-based regimens on QoL among treatment naïve participants [39, 43, 44]. In the case of Pimentel et al., the studied cohort was exposed to DTG-based ART and another comparator ART regimen and followed up longitudinally. One paper reported on the impact of DTG-based regimens on QoL among treatment experienced PLHIVs that received the regimens as first line therapy [40]. Five studies compared the effect of DTG-based regimens to other ARTs on QoL either through randomization [37, 41, 42] or transition to the interventional therapy (switch trials) [38, 51]. Impact of DTG-based regimen on treatment naïve PLHIV The three studies that reported on the effect of DTG-based regimens among treatment naïve patients presented statistically significant results (See Appendix 4). Mendes et al. found high mean scores across all six domains of WHOQOL-HIV BREF among PLHIV exposed to DTG/3TC/TDF and an overall score of 15.5 [43]. Pimentel et al. reported on statistically significant improvements in the overall QoL and in five domains of WHOQOL-HIV BREF among PLHIV initiating DTG/3TC/TDF [44]. Overall mean QoL score was 16.77 compared to 16.11 of the comparator ART. Patient-reported data of 203 HIV positive women were analyzed in another study [39]. At 24 weeks, changes from baseline were significant for general health perception (p < 0.0001) and cognitive function (p < 0.05). Among pregnant women on DTG-based regimens, there was no significant differences in QoL in comparison to those on EFV-based ART. At 48 weeks, DTG treated women reported more improvement in QoL though differences between the interventional group and the EFV group were still not statistically significant. Comparison of the effects of DTG-based regimens to other ART on QoL Six studies of the eight primary studies that reported on the effects of DTG on QoL compared the study outcome between interventional and comparator regimens. Findings from four of the six papers favored DTG-based regimens. Sculier et al. reported a change in QoL between baseline and week 48 data in both DTG/FTC and cART arms [41]. In the DTG/FTC arm, the mean change was + 2.9 points compared to + 0.3 points in the cART arm, with this difference statistically significant (p = 0.023). A randomized controlled trial that used PROQOL-HIV to assess PS in DTC/FTC and cART arms reported high satisfaction of > 80/100 in both arms at week 144. Nevertheless, the study concluded there were no significant differences between both treatment groups [42]. A cohort study showed improved QoL scores after transitioning from an NVP-based regimen to DTG-regimen though this difference was not significant [51]. One study concluded there were no overall QoL differences between DTG- and EFV-regimens but reported higher scores in the physical and spiritual domains of the WHOQOL-HIV BREF among the DTG group [38]. Impact of DTG-based regimens on PS Six out of the 9 papers (8 primary and one dual outcome) that reported on PS were on PLHIV who switched from a different ART regimen to a DTG-based regimen [45–47, 49–51]. Hence, in these studies, PLHIV were already ART experienced before the initiation of DTG-regimens. Additionally, three studies included either treatment naïve or DTG-experienced PLHIV [20, 22, 48]. Patient satisfaction data was collected through a survey among a cross section of patients on DTG-based ARTs and EFV- as well as LPV-based ARTs. Baseline data on PS before DTG initiation were not provided in two of these studies, hence we could not pool effect sizes to make comparison pre and post regimen initiation. Impact of DTG-based regimens on PS among treatment naïve PLHIV Using the HIVTSQ tool, one study reported a higher mean score of 5.01 among PLHIV newly initiated DTG-based regimens compared to 4.81 among those exposed to Lopinavir-based regimens, with the difference not statistically significant (p = 0.06) [20]. Another study which used the EQ-VAS to measure satisfaction level reported a mean score of 90 (IQR: 80–85) among treatment naïve patients initiated on DTG-based regimens at week 4. At week 24, satisfaction level was scored at 90 (IQR: 85–100). All patients in the study were reported to have 100% adherence to treatment as well, with no missed follow-up visits [48]. In a referral center in Ethiopia, where TSQM was used to assess patient satisfaction among PLHIV on TDF/3TC/DTG, median effectiveness score was reported to be 83.3. The median convenience score was also reported as 83.3 (IQR: 77.7–100) as well as a median global satisfaction of 83.3 (IQR: 75–100) (See Appendix 5). Comparison of the effects of DTG-based regimens to other ART on PS Four of the six studies that focused on the effects of DTG-based regimens on PS after switching from an alternative ART reported positively on the study outcome. In one study, overall median satisfaction was high among patients on ABC/3TC/NVP and those switched to ABC/3TC/DTG. However, at week 12, there was relatively improved change in satisfaction with the new treatment group. At week 48, median score among the new treatment group was 58 using the HIVTSQ compared to 54 in the ABC/3TC/NVP [47]. Kumar et al. also reported mean HIVTSQ scores between DTG/3TC group and another group on combined ART sustained through 48 weeks [46]. Mean HIVTSQ scores for the DTG/3TC (55.2) and cART (55.8) arms were high and similar at baseline. PLHIV who were switched to DTG/3TC reported sustained improvements in satisfaction compared to the early group, with mean change in PS at week 4 (1.8[0.9–2.6]), week 24 (1.4[0.7–2.2]) and week 48 (1.4[0.7–2.2]). Further, among ART experienced PLHIV who had attained virological suppression and switched to ABC/3TC/DTG, mean score of HIVTSQ was reported as 57 compared to 53 among those that continued with the existing ART [49]. In Indonesia, among 145 PLHIV who transitioned from an NVP- to DTG-based ART and eligible for the study analysis, there was a significant increase in EQ VAS scores [51]. Six months after transition before median score was 90 (IQR: 80–99) compared to 90 (IQR: 85–100), p < 0.001. Also, from 23.4% of participants who had a VAS score of 100, after the transition, 38.3% of the study population reported VAS scores of 100. Comparison of the effects of DTG-based regimens to other INSTI-based regimens on PS Two studies compared the effects of DTG-based regimens to other ARTs with INSTI-backbone. Both studies showed lower PS among PLHIV on DTG-based ART than those on other ART. A cohort study that assessed PS among 43 PLHIV on DOR/DTG and 52 PLHIV on DOR/RAL combinations followed up on both groups for a mean of 37 weeks [45]. Using the HIVTSQ tool, a general high level of satisfaction among the cohorts was reported to be 64 [54–68]/72). However, significantly higher scores were observed in the DOR/RAL cohort (68 [64–72]/72) compared to DOR/DTG (58 [50–65]/72) respectively, p < 0.001). Similarly, a randomized controlled trial that randomized PLHIV to continue with DTG/ABC/3TC or switch to BIC/FTC/TDF showed no differences in TSQM scores at between both arms at baseline [50]. After three months, PS was higher in the late switch group (6.5 ± 0.78) compared to those on DTG/ABC/3TC (5.47, DS ± 1.89), p = 0.03. Meta-analysis of the effects of DTG-based regimens on QoL and PS In conducting the meta-analysis of the effect of DTG-based regimens on both QoL and PS, we observed some considerations prior to pooling. We extended these considerations to the meta-analysis of the subgroup of measurement tools. Statistical considerations for cross-instrument comparability We observed pre-expected variations in the instruments used to assess QoL and PS across all included studies. Some studies reported outcomes as medians and IQR [38, 45, 47, 48, 51] while some studies reported means and standard deviations [20, 37, 39, 40, 43, 50]. Thus, pooling raw scores across QoL and PS measurement tools was not feasible as the instruments identified in all included studies were different in terms of scale, scoring method and direction. Therefore, we applied our standardization strategy prior to pooling as described in the Methods section. All outcomes were expressed as Hedges’ g, SMD (See Table 2), Unit of analysis decisions Following data extraction, we made some decisions to ensure that each study contributed one independent effect size per outcome prior to pooling. For studies reporting outcomes at multiple follow-up time points, we selected the longest time point of 48 weeks [39, 41, 46, 49]. One study reported more than one measurement instrument. Costa et al. reported outcomes for both the WHOQOL-HIV BREF and the EQ-5D [38]. The authors stated that EQ-5D scores were solely for normative comparison against the Brazilian population reference values and not for between-group comparative outcome. Therefore, for this study, we extracted the data of the WHOQOL-HIV BREF for pooled analysis. Additionally, Hong et al. reported PS scores for three regimen groups from the same study population, DTG, EFV and LPV/r [20]. To avoid double counting the DTG arm, a simple comparator was selected for pooling. We designated EFV the primary comparator as the most clinically relevant non-DTG first-line reference regimen while LPV/r comparison was retained in the narrative synthesis. Meta-analysis of effect of DTG-based regimens compared to other ART on QoL To quantify the impact of DTG-based regimens on QoL in comparison to other ART, we conducted a meta-analysis using only studies that provided data on comparative QoL. Only six studies were included for the meta-analysis [38–41, 43, 44]. Meta-analysis showed a small positive effect on QoL among PLHIV on DTG-based regimens (SMD = 0.094, 95% CI = -0.03–0.22) compared to other ART (Fig. 2). Forest plot of effect sizes for studies assessing the impact of dolutegravir-based regimens vs. other antiretroviral therapies on quality of life This effect was not statistically significant (p = 0.15), though with a low heterogeneity (I2 = 37.1%). Using the funnel plot, there was no indication of marked symmetry, suggesting no evidence of publication bias (See Appendix 2). This evidence was supported by the output of the Egger’s regression test (p = 0.4). Details of the meta-analysis are summarized at Table 3. Table 3Summary of results of the meta-analysis of the effect of DTG-based regimens on QoL and PS in comparison to other ART regimensOutcomeNumber of studiesSMD95% CIp-valueI2Egger’s test(p-value)QoL60.094− 0.034, 0.2230.1537.10.4PS40.30.2, 0.4< 0.00110.70.63QoL by WHOQOL BREF30.09− 0.042, 0.220.1810.00.62PS by HIVTSQ30.320.2–0.45< 0.001340.33QoL: Quality of Life; PS: Patient Satisfaction; ART: Antiretroviral therapy; SMD: Standardized Mean Difference; CI: Confidence Interval; DTG: Dolutegravir Summary of results of the meta-analysis of the effect of DTG-based regimens on QoL and PS in comparison to other ART regimens QoL: Quality of Life; PS: Patient Satisfaction; ART: Antiretroviral therapy; SMD: Standardized Mean Difference; CI: Confidence Interval; DTG: Dolutegravir Meta-analysis of effect of DTG-based regimens compared to other ART on PS To quantify the impact of DTG-based regimens on PS in comparison to other ART, we conducted a meta-analysis using only studies that provided data on comparative PS. Five of the nine studies that reported on PS were excluded from the meta-analysis. Poliseno et al. was adjudged by the reviewers to have high bias and Rossetti et al. compared two INSTI classes. Three studies had no comparator arms. Thus, four studies were included for the meta-analysis ([20, 46, 47, 49]. The meta-analysis gave a small positive effect on PS among PLHIV exposed to DTG-based regimens (SMD = 0.308, 95% CI = 0.2–0.40) compared to those on other ART. This effect was statistically significant (p < 0.001), with a low heterogeneity (I2 = 10.7%) (Fig. 3). Egger’s regression test did not indicate publication bias (p = 0.628). Forest plot of effect sizes of studies assessing the impact of dolutegravir-based regimens vs. other antiretroviral therapy on patient satisfaction among persons living with HIV Meta-analysis of effect of DTG-based regimens on QoL and PS per measurement tool We also pooled the effect of DTG-based regimens on the outcomes from studies that reported the use of a measurement tool more than once. Using the WHOQOL-HIV BREF tool, three studies with three effect sizes reported on QoL [38, 40, 44]. The meta-analysis showed a small positive effect of DTG-based regimens on QoL (SMD = 0.09, 95% CI = -0.042–0.22, p = 0.181, I2 = 0.0%). Three studies using HIVTSQ were pooled to estimate the effect of DTG-based regimens on PS [46, 47, 49]. The instrument-specific meta-analysis using HIVTSQ demonstrated a statistically significant small effect favoring DTG-based regimens (SMD = 0.328, 95% CI = 0.2–0.45), p < 0.001, I2 = 34%). There was no marked symmetry in the funnel plots, and these observations were complemented by the results of the Egger’s test. All forest and funnel plots for the instrument subgroup analysis are provided in the Supplementary Material (See Appendix 3). We limited subgroup analysis to measurement tools as additional analysis by geographical region and study design subgroups were insufficient to yield interpretable estimates. For instance, three of six QoL studies were conducted in Brazil and one each from Africa and Europe, a distribution that would render geographical subgroup analysis unreliable and unrepresentative of the regions. Proportion of PLHIV satisfied with DTG-based regimens Four studies reported on the proportion of PLHIV satisfied with different DTG-based regimens [20, 41, 46, 49]. Among 78 new patients initiated on DTG-based regimens, 49 (62.8%) were reported to be satisfied with their treatment compared to 61% and 54.4% who were satisfied with Lopinavir and EFV-based ART. Among existing patients who continued with their medication, satisfaction was high among the DTG group at 66.2%, compared to 38.3% and 53.3% for the Lopinavir and EFV groups respectively [20]. A cross-sectional study of 349 DTG-experienced PLHIV reported a high treatment satisfaction of 70.5% [22]. In a randomized controlled trial, out of 188 PLHIV on cART, 93 were assigned to DTG/FTC arm while 94 continued on the existing cART. After 48 weeks of study period, 85.6% of patients on DTG/FTC decided to remain on their regimen [41]. Another randomized, multicenter study that assigned 246 and 247 PLHIV to DTG/3TC and cART arms respectively reported similar findings [46]. At 48 weeks, PS was high in both groups, with 100% of those that experienced DTG satisfied with their regimen and 98% on cART reporting satisfaction as well. In summary, from the four studies that reported on proportion of PLHIV satisfied with DTG-based regimens, PS ranged from 62.8% − 100%. Factors associated with the review outcomes Three studies reported on the factors associated with QoL [38, 40, 44] while three studies reported on PS predictors [20, 22, 46]. Factors associated with QoL among PLHIV on DTG-based regimens The factors associated with QoL were thematically synthesized into five main domains: sociodemographic, behavioral, socioeconomic, psychosocial and clinical factors. Sociodemographic factors: Education was reported as a predictor of QoL in two studies. Gudala et al. reported that education level was significantly associated with improved QoL while in Costa et al., those with lower level of education had lower QoL compared with those with high level of education [38, 40]. Social support was reported in two studies either as living with family or marital status. One study identified living with family or people as associated with improved QoL [44]. In the study, living with family was associated with improved QoL (ᵝ= -5.80, 95% CI: -9.60, -2.00, p = 0.003). Also, lower QoL was associated with being single either through divorce or widowed [38]. Behavioral factors: Two factors were identified as behavioral predictors of QoL. Lower QoL was reported as associated with the recent history of smoking cigarette [38]. Also, PLHIV classified as ≥ 95% aherent to DTG-based regimens indicated superior QoL compared to those non-adherent [40]. Socioeconomic factors: Gudala et al. reported an association between income and PS among PLHIV (ᵝ= 0.72, p = 0.0). PS increased with increasing income range, with those earning above 5000 rands reported to have the highest PS score [40]. Psychosocial factors: Two studies found that the presence of signs and symptoms of anxiety and depression were predictors associated with worsening QoL [38, 44]. Gudala et al. and Pimentel et al. reported a good perception of illness and having religious belief respectively as being associated with increase in QoL [40, 44]. Clinical factors: The most reported clinical predictor of lower QoL was the occurrence of adverse drug reactions. This predictor was reported in two studies [38, 44]. Additionally, being comorbid was identified as associated with worsening QoL [38]. Longer duration on DTG-based regimen was found to be a significant predictor of QoL (ᵝ=0.52, 95% CI: 0.12, 0.91, p = 0.01) [38, 60]. Factors associated with PS among PLHIV on DTG-based regimens Three studies reported on the predictors of PS among PLHIV exposed to DTG-based regimens. These factors were thematically synthesized under the following domains: Socioeconomic: Unemployment was a predictor of low likelihood of PS, with PLHIV on part time jobs having a lesser likelihood of PS compared to those on full time employment (aOR = 0.49, 95% CI: 0.22–0.90) [20]. Increased monthly income was another socioeconomic predictor associated with PS. Moderate monthly income was associated with improved PS (AOR: 2.47; 95% CI: 1.11–5.48) and this increased with high monthly income (AOR: 3.11; 95% CI: 1.31, 7.37). Psychosocial: History of injection drug use correlated with worsening PS [20] while PLHIV who had a positive belief about medications were associated with improved PS [22]. Clinical: Hong et al. studied a cross-section of PLHIV on DTG-based and LPV-based combinations and reported on the PS of both groups. PLHIV starting ART with DTG had higher satisfaction with treatment compared to people continuing LPV-based regimens (aOR = 0.49, 95% CI: 0.22–0.90). Also, PLHIV without other concurrent medications and those that benefited from counselling with healthcare providers were associated with improved satisfaction [22]. Sociodemographic: The male gender (aOR: 2.10, 95% CI: 1.14, 3.87) was reported to be predictor of improved PS [22]. Risk of bias assessment Assessment of quality of studies was guided by the type of study designs of the included papers. Six cross-sectional studies were assessed using the Newcastle-Ottawa scale [20, 22, 38, 40, 43, 60]. The JBI Checklist for Cohort Studies was used to assess the quality of the three cohort studies [44, 45, 51]. The CASP Checklist for RCTs was used to evaluate the quality of the included RCTs in the review [39, 41, 42, 46, 49, 50] while the ROBINS-I V2 tool was utilized in assessing the non-randomized interventional studies [47, 48]. Summary of the reviewers’ decision for studies included in the meta-analysis is at Table 4. Table 4Table showing the summary of quality assessment for all included studiesStudy Design of Included PapersBias Assessment per Number of StudiesLowModerateHighCross-sectional5--Cohort-21RCT43-Non-randomized-2- Table showing the summary of quality assessment for all included studies Quality assessment for cross-sectional studies All five cross-sectional studies evaluated for quality using the Newcastle-Ottawa Scale for Cross-Sectional studies had low risk of bias. However, four of the five studies failed in the domain of appropriateness of sample size as the sample sizes in the studies were below the threshold of 400 specified by the tool [22, 38, 43]. Additionally, one study did not pass the domain of representativeness due to sampling strategy issues. For instance, Mendes et al. used the convenience sampling technique. Nevertheless, all five studies passed the domains of outcomes assessment, the use of appropriate statistical test and reportage on response rate. Thus, all the cross-sectional studies were included in the narrative review and those that met the eligibility criteria of the meta-analysis were also included. Quality assessment for cohort studies The risk of bias assessment for the three cohort studies was done using the JBI Checklist for Cohort Studies. Two studies were graded as having moderate risk of bias [44, 51]. While both studies presented similarity in the recruited cohorts, similarity in exposures between groups and identified confounders, reviewers adjudged that the studies failed to pass the ‘Absence of Outcomes at Moment of Exposure’ domain. This is because baseline figures presented indicated that the cohorts investigated had good PS even before regimen switch hence the intended outcome was present. Nevertheless, one study was adjudged to have a high risk of bias. In addition to failing the ‘Absence of Outcomes at Moment of Exposure’ domain, reviewers adjudged the study to fail in identifying potential confounders. For instance, 64% of the cohorts on DTG/DOR combination were hypertensive compared to the RAL/DOR group and this difference was statistically significant (p = 0.009). Also, in measuring exposures between cohorts, those switched to the DTG/DOR combination had eight years of viral suppression prior compared to the RAL/DOR group which had 12 years of viral suppression before regimen. This difference was also statistically significant. The study also failed in the domain on the percentage loss to follow-up. The Checklist suggests that the loss of 5% or less could be considered insignificant. Nevertheless, 8% of the DOR/RAL group discontinued from the study compared to 4% in the DTG/DOR group. Quality assessment for RCTs The CASP tool was used to assess the risk of bias for the RCTs. Four RCT studies were adjudged [37, 41, 46, 49] as low-bias studies and remaining three studies were declared to have a moderate risk of bias [39, 42, 50]. All seven studies provided clear research objective, randomized the participants, presented that randomized groups were similar and had similar follow-up periods. However, all the studies were open-label and hence neither the participants or investigators were blinded. Quality assessment for non-randomized interventional studies The ROBINS-I V2 Checklist was used to assess the two non-randomized interventional studies [47, 48]. Both studies did not provide information on the handling of confounding and missing data. The studies, however, reported outcomes appropriately, presented there were no confounding post-intervention variables and that study design met the criteria of intended interventions. Both studies were scored to have moderate risk of bias. Certainty of evidence For the effect of DTG-based regimens on QoL, the certainty of evidence was rated Very Low across both analyzed pools. The primary QoL analysis started at Moderate certainty, considering there were three contributing RCTs out of the six studies. This status was downgraded twice due to the serious risk of bias and the imprecision of confidence intervals. This was similar to the grading of the finding from the WHOQOL-HIV BREF subgroup. Despite the observed low heterogeneity here, grading was rated Very Low because of the imprecision of confidence intervals and the presence of open-label RCTs. For PS, certainty was rated as Low for both the primary and subgroup results. While studies that contributed to the analysis dominated RCTs, grading of the findings were downgraded to Low as a result of the open label RCTs (See Table 5). Table 5Summary of the grading of recommendatins assessment, development and evaluation: effect of DTG-based regimens on quality of life and patient satisfactionOutcomeStudy DesignRisk of BiasInconsistencyIndirectnessImprecisionPublication BiasPooled Result (g; 95% CI; p)CertaintyQoL: Overall (DTG vs. comparator ART)3 RCTs, 1 cohort, 2 cross-sectional Start: ModerateSerious (− 1) Open-label designs; patient-reported outcomes susceptible to performance bias; 2 observational studies includedNot serious I²=37.1%; (p = 0.16); five of six studies directionally favour DTGValidated QoL tools used: no downgradeSerious (− 1), CI crosses nullUndetectedSMD = + 0.094 95% CI (− 0.034, + 0.223) p = 0.15. Non-significantVERY LOWQoL: WHOQOL-HIV BREF subgroup1 cohort, 2 cross-sectional Start: Low (all observational)Serious (− 1) Observational designs; no blinding;Not serious I²=0.0%; all three studies favour DTGIdentical QoL tool and identical regimen (DTG/TDF/3TC): no downgradeSerious (− 1), CI crosses nullUndetectedSMD = 0.09; 95% CI (− 0.042, + 0.22), p = 0.181. Non-significantVERY LOWPatient Satisfaction: Overall (DTG vs. comparator ART)2 RCTs, 1 cross-sectional, 1 pre-post single arm. Start: ModerateSerious (− 1) Open-label RCTs; pre-post designNot serious I²=69.4%; all four studies favour DTG-based regimensValidated PS tools used: no downgradeNot serious, CI excludes nullUndetectedSMD = 0.32, 95% CI (0.2, 0.4) p < 0.001, Statistically significantLOWPatient Satisfaction:HIVTSQ subgroup2 RCTs, 1 pre-post single arm Start: ModerateSerious (− 1) Open-label RCTs; pre-post designNot serious I²=34.0%; all three studies favour DTGIdentical PS tool: no downgradeNot serious CI excludes nullUndetectedSMD = 0.32; 95% CI (0.2, + 0.45); p < 0.001, Statistically significantLOWDTG = dolutegravir; QoL = quality of life; CI = confidence interval; RCT = randomised controlled trial; HIVTSQ = HIV Treatment Satisfaction QuestionnaireCertainty assessed using the GRADE framework. Starting certainty for mixed evidence bodies (RCTs + observational) = Moderate; for bodies comprising observational studies only = Low. Downgraded − 1 for serious concern, − 2 for very serious concernPublication bias assessed with output of Egger’s test Summary of the grading of recommendatins assessment, development and evaluation: effect of DTG-based regimens on quality of life and patient satisfaction Patient Satisfaction: HIVTSQ subgroup DTG = dolutegravir; QoL = quality of life; CI = confidence interval; RCT = randomised controlled trial; HIVTSQ = HIV Treatment Satisfaction Questionnaire Certainty assessed using the GRADE framework. Starting certainty for mixed evidence bodies (RCTs + observational) = Moderate; for bodies comprising observational studies only = Low. Downgraded − 1 for serious concern, − 2 for very serious concern Publication bias assessed with output of Egger’s test Discussion To the best of our knowledge, this is the first systematic review and meta-analysis that has synthesized evidence on the effect of DTG-based regimens on QoL and PS. This review was carried out with data from 17 eligible papers. The studies were set in North America, South America, Europe, Asia and Africa. Studies were largely RCTs and cross-sectional studies. Outcomes were assessed by a wide range of validated measurement tools. This review synthesized evidence involving 4064 PLHIV receiving different DTG-based regimens. The meta-analysis of six QoL studies demonstrated a consistent positive directional trend favoring DTG-based regimens, with a small, pooled effect size (SMD = 0.094; 95% CI: -0.034 to 0.223; p-value = 0.15). Among studies that measured QoL with the WHOQOL-HIV BREF tool, a small positive effect was also observed, with an observed internally homogeneous analysis (SMD = 0.09; 95% CI: -0.042 to 0.22), underscoring the consistency of the directional trend in QoL. For PS, the meta-analysis demonstrated a statistically significant small effect favoring DTG-based regimen (SMD = 0.3; 95% CI: 0.2 to 0.4; p < 0.001; I2 = 10.7%). This was further reinforced for studies that used only the HIVTSQ tool (SMD = 0.32; 95% CI: 0.2 to 0.45; p < 0.001; I2 = 34%). Findings from this study suggest that DTG-based regimens may confer measurable patient-centered benefits. Nevertheless, certainty of evidence was related Very Low for QoL and Low for PS using the GRADE assessment framework, noting the dominance of open-label designs and observational studies as well as the imprecision of effect sizes. Accordingly, findings from this review are characterized as hypothesis-generating as they establish more directional signals. Therefore, caution should be applied in the context of interpretations. The finding that DTG-based regimens improved QoL and PS aligns with the fact that ART generally enhanced patient-reported outcomes among PLHIV [61]. In this present review, we reported [43] that there was a high proportion of PLHIV satisfied with their DTG-based regimens, with a range of 62–100%. These findings with regard to the comparison of the effect of DTG-based regimens and other ART on our study outcomes is consistent with previously published work. Evidence suggests that INSTI-based regimens generally improved patient-reported outcomes such as QoL and PS in comparison to NRTI or booster ART [62–64]. While we noticed paucity of high-quality studies in this review as well as low to very low certainty of evidence in findings, we posit that the observed improvement in study outcomes after the initiation of the regimens can be attributed to some reasons. First, there is available evidence that indicates that DTG-based regimens have superior action on viral suppression compared to other cARTs. A meta-analysis of RCTs including > 6400 PLHIV found that DTG-based regimens had increased likelihood of achieving viral suppression and lower rates of discontinuation compared with non-DTG containing ART [65]. In another systematic review, Doblado-Maldonado et al. also reported that switching to DTG-3TC regimen resulted in high proportions of PLHIV achieving virologic suppression at different time points [66]. This finding is also consistent among children and comorbid PLHIV exposed to DTG-based combinations [24, 67, 68]. An earlier review had established that ART generally improved QoL among PLHIV [69]. Gakhar et al. stated that even when there was a general decline between a group initiated on the zidovudine (AZT) ART and a placebo group, the decline was less among the AZT group. In the review paper, the authors presented evidence of the direct correlation between clinical progression parameters such as the CD4 count and viral load, and QoL. They argued that as CD4 count increased and viral load decreased, there was the tendency for QoL to improve. Hence, this is a plausible reason for the reported higher QoL magnitude among PLHIV on DTG-based regimens compared to other ART in this study. Another plausible reason for improved patient-reported outcomes in the DTG group, as observed in this study, could be related to adherence. Adherence and QoL are intertwined, with adherence linked to improved QoL among PLHIV. Also, as QoL and satisfaction improves, PLHIV are believed to in turn have enhanced adherence [70]. Therefore, there is the suggestion that patients who poorly adhere to ART would ultimately have increased viral load and subsequently, low QoL as clinical parameters worsen [71]. While ART adherence is key for PLHIV, there is emerging evidence that DTG has a high degree of ‘forgiveness’ for missed doses compared to other regimens. A cohort study, with a follow-up period of 4 years demonstrated that 96% of PLHIV on non-DTG regimens attained viral suppression when adherence was 90% [72]. However, when adherence was between 0–49%, viral suppression was 32% points lower. Conversely, for PLHIV on DTG-based regimens, > 95% attained viral suppression regardless of adherence levels. Thus, viral suppression is attainable among PLHIV on DTG-based regimens despite low adherence levels. Key to state that in this review, only one study mentioned adherence as a predictor of QoL [40]. Implications are that even in situations where adherence is low, DTG will retain a comparative advantage on viral suppression compared to other non-DTG regimens and consequently on QoL. Third, long-term use of ART is associated with cardiovascular diseases (CVD), making such diseases the primary cause of deaths among PLHIV [73]. Studies have shown that dyslipidemia is responsible for 50% of the overall CVD risk, resulting in recommendations that the selection of lipid-friendly regimens will reduce the CVD burden and improve QoL among PLHIV. In this regards, DTG-based regimens have shown better lipid profiles compared to certain ART. For instance, a cohort study of 64 PLHIV diagnosed dyslipidemia and subsequently switched from EFV to DTG reported that at week 24, DTG resulted in lower mean total cholesterol, low-density lipoprotein cholesterol and triglycerides [74]. In another study, PLHIV who were switched from Ritonavir-boosted protease inhibitors to DTG-based regimens had a 7.7% reduction in low-density lipoprotein cholesterol from baseline values [75]. The authors argued that switching ART to improve lipid profiles is a supplemental strategy to the use of lipid-lowering agents. In this review, we reported that most of the comparator regimens were EFV-based regimens. Thus, it is plausible to state that DTG-based regimens presented QoL advantages as a switch choice by reducing lipid profiles while maintaining viral suppression among PLHIV. This systematic review and meta-analysis also synthesized evidence on the factors associated with QoL and PS. There were more factors in the clinical and sociodemographic domains reported to be associated with QoL. Specifically, the occurrence of ADRs and comorbidities in the clinical domain as well as education status and social support, both under the sociodemographic domain, were the most reported factors. Consistent with our findings, studies have reported statistically significant associations between education and QoL among PLHIV on ART [76, 77]. It is believed that those with higher education levels have higher odds with compliance to advisories on healthy lifestyle and medication adherence. With regards to comorbidity, there is available evidence of the relationship between comorbidity and lower QoL scores [78, 79]. For instance, a prospective, cross-sectional study found that non-comorbid PLHIV respondents had a higher QoL scores compared to comorbid respondents [80]. In the study, a statistically significant association between the presence of comorbidity and low QoL was reported. The authors posited that the observed difference could be due to the burden of symptoms associated with the other morbidities, which could impair QoL. Notably in the paper, comorbidity was defined as the presence of two or more chronic diseases. In our study, social support encompassed living with people and being married or living with a partner. Studies that reported the influence of social support on high QoL scores among PLHIV have attributed it to the emotional, financial and safety support that families offer to their HIV-positive partners. Also, non-discrimination and acceptance within the community have also been attributed to better QoL scores [15, 80]. Furthermore, ART-induced ADRs is a challenge in the management of PLHIV [81, 82]. It is established that ART-induced ADRs can cause varying adverse effects, affect organ systems, with the occurrences of these ADRs significantly impacting QoL [82]. Noting the range of QoL predictors among PLHIV on ART regimens, DTG-based combinations inclusive, findings from this study underscore the adoption of patient-centred, multidisciplinary approach to the management of HIV. Implications of findings for practice and policy The SMD reported for QoL and PS in this study, though small indicates that DTG-based regimens possess advantages over certain cART. Findings from this study suggest that DTG-based regimens may offer meaningful benefits in terms of patient reported outcomes such as QoL and PS. Thus, clinicians should consider routinely assessing patient-reported outcomes by using validated instruments when initiating or switching ART. By doing this, alongside other clinical markers, clinicians would better capture dimensions of treatment response. Additionally, by interpreting primary findings of this review alongside the reported range of proportions of PLHIV satisfied with DTG-based regimens, we also present the most currently available quantitative evidence that DTG-based regimens may offer QoL and PS benefits, a hypothesis that clinicians can consider when counselling on regimen selection, while evidence from well-designed trials in this area is still required. Additionally, for PLHIV at risk of CVD, and on EFV-regimens or booster medications, our study provides further supporting evidence that a switch to DTG-based regimens could improve QoL by reducing lipid profiles. Further, considerations should be given to non-clinical determinants of patient-reported outcomes as there is substantive evidence to show their associations with QoL and PS. Specifically, enhanced counselling should be targeted at PLHIV with lower educational status as education levels and health enlightenment were shown to be predictors of QoL. From a policy perspective, given the reported benefits of DTG-based regimens for QoL and PS, HIV program managers should prioritize these regimens in differentiated service delivery programs. This will in turn improve patient experience through optimal viral suppression and increase levels of retention. Ultimately, our findings reinforce proposals that measuring patient-reported outcomes should be prioritized as much as clinical parameters. Implications of findings for future research In conducting this study, we observed two areas with implications for future research. First, in this systematic review and meta-analysis, we broadly examined all DTG-based regimens. Thus, future research should aim to focus on specific components of DTG-based regimens and evaluate their impacts on QoL and PS in comparison to other regimens. Such study would provide evidence on specific DTG-based regimens with comparative advantage with regards patient-reported outcomes. Second, we observed that certain populations such as children, adolescents and older patients were underrepresented. Only one study in the review focused on pregnant women. Given that improvement in patient-reported outcomes such as QoL and PS are predictors of retention and viral suppression, it is key for future studies to assess the impact of DTG-based regimens on outcomes among these populations. Therefore, well-designed observational studies focusing on underrepresented populations will provide further evidence on the possible impact of DTG on patient-reported outcomes. Additionally, as more studies continue to focus on the impact of DTG-based regimens on patient-reported outcomes, the potential for an updated meta-analysis to assess the consistency of these findings will remain. Strengths and limitations Findings from this systematic review and meta-analysis should be interpreted in the context of some limitations. First, we note the low and very low certainty of evidence in the primary findings of the meta-analysis, possibly as a result of the dominance of open label trials. We also acknowledge not attempting to fully assess the reason for the heterogeneity through a meta-regression or sub-group analysis since the number of studies included for each outcome was < 10. Nevertheless, we complemented our analysis with a narrative review which indicated support for our findings. Notably, in the meta-analysis, when we analyzed the impact of the DTG-based interventions on outcomes by measurement tool, there was low heterogeneity per QoL and PS. Second, this study measured the magnitude of the impact of interventions using SMD. SMD has inherent limitations, especially where outcomes are measured with different instruments. There is also the notion that clinicians may not be able to easily interpret SMDs and relate it to real world settings. Third, this paper did not include grey literature and abstracts as both could introduce a potential source of publication bias. With this decision, there is the chance we could have missed out on other findings from these sources. On this, we state that our decision to exclude this form of papers from this review was to ensure validity of our findings and guarantee the robustness of our results through inclusion of studies that had passed through the rigor of the peer-review process. Notable to state that the Egger’s regression test for both QoL and PS studies did not indicate any publication bias. Lastly, we included studies only published in English and would have missed out on other papers, further potentially introducing publication bias. This study possesses some major strengths and provides value for the discourse on HIV management. First, this is the first systematic review and meta-analysis to have comprehensively synthesized evidence on patient-reported outcomes among PLHIV receiving DTG-based regimens. Through this, we provided valuable insights into the impact of DTG-based regimens on QoL and PS and also synthesized evidence on the factors influencing these outcomes among PLHIV. Second, the low between-study heterogeneity observed across the primary analysis for studies that used same measurement tools indicate that the directional trend toward QoL and PS with DTG-based regimens is consistent. Third, rigorous attention was paid to the methodological conduct of this review. Gallardo-Gomez et al. provided the common pitfalls in using SMDs [34]. For example, Gallardo-Gomez et al. mentioned the inappropriate use of SMDs without justification and the mistake of reviewers not providing interpretation for SMDs. We gave particular attention to each of these pitfalls to ensure the robustness of our findings. Specifically, the use of SMDs was justified by the heterogeneity of measurement instruments across included studies. We followed up by interpreting pooled SMD estimates using the proposed Cohen’s magnitude thresholds. Additionally, transparency was maintained in the conduct of this review. All effect size transformation procedures were pre-specified and documented. Lastly, we maintained transparency in our methods by first registering and publishing the protocol in a peer-reviewed journal prior to data extraction and analysis. We then made conscientious efforts to limit researchers’ by subsequently, adhering to the study objectives. Conclusion Current HIV treatment guidelines recommend the use of DTG for first- and second-line management of HIV. Supporting evidence indicates the favorable safety and efficacy profile of DTG. Nevertheless, evidence of the impact of DTG on patient reported outcomes such as QoL and PS remains scanty. This review aimed to assess the impact of DTG-based regimens on QoL and PS as well as synthesize the evidence on the factors associated with these outcomes. We reported that there was a small improvement in QoL and PS among PLHIV exposed to DTG-based regimens compared to other ART. Nevertheless, this finding should be interpreted cautiously, considering the low and very low certainty of evidence with regards to the effect of DTG-based regimens on PS and QoL respectively. Hence, results from this study are best characterized as hypothesis-generating and supportive of person-centered HIV care, underscoring the need for more well-designed trials to generate high-certainty evidence on patient-reported outcomes among PLHIV Ultimately, our study supports the need for HIV programs to give attention to patient-centered care by routinely measuring patient-reported outcomes. Electronic Supplementary Material Below is the link to the electronic supplementary material. Supplementary Material 1 Acknowledgements Not applicable. Abbreviations Dolutegravir Human immunodeficiency virus Quality of Life Antiretroviral therapy Patient satisfaction Persons living with HIV Cardiovascular diseases Efavirenz Standardized Mean Differences Nucleoside reverse transcriptase inhibitor Integrase strand transfer inhibitors Randomized Clinical Trials Critical Appraisal Skills Program Confidence intervals Author contributions BUK, MMA, and AI conceptualized the design of the study and wrote the. BUK, MMA, AI, RJ and GE did the literature searches. MMA, COO, IKI, LE, and YD screened the articles for inclusion. MMA, RJ, AI, COO, IKI, LE, YD, SM, SUJ, AMB, APN, GE and BUK extracted data for analysis. MMA undertook the meta-analysis and produced forest plots and summary results, under the supervision of AI and BUK. MMA and BUK wrote the first draft of the manuscript. All authors revised the manuscript and approved the final version. Funding There was no funding source for this study. Data availability The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate No ethics review was required as the study involved analysis of published studies. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.